The development of hydroxyl-dendrimer-GLS1 inhibitor conjugates, D-TTM020 and D-JHU29, represents a significant advancement in targeted depression treatment, offering the potential for improved efficacy and safety compared to traditional therapies. This evidence concerns the gene GLS and major depressive disorder.